WO2004021974A3 - Non-psychotropic cannabinoids for prevention of cognitive impairment - Google Patents

Non-psychotropic cannabinoids for prevention of cognitive impairment Download PDF

Info

Publication number
WO2004021974A3
WO2004021974A3 PCT/IL2003/000735 IL0300735W WO2004021974A3 WO 2004021974 A3 WO2004021974 A3 WO 2004021974A3 IL 0300735 W IL0300735 W IL 0300735W WO 2004021974 A3 WO2004021974 A3 WO 2004021974A3
Authority
WO
WIPO (PCT)
Prior art keywords
cognitive impairment
prevention
certain types
populations
psychotropic cannabinoids
Prior art date
Application number
PCT/IL2003/000735
Other languages
French (fr)
Other versions
WO2004021974A2 (en
Inventor
Seth Kindler
Aaron Garzon
George Fink
Original Assignee
Pharmos Corp
Seth Kindler
Aaron Garzon
George Fink
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2003/000604 external-priority patent/WO2004023340A2/en
Application filed by Pharmos Corp, Seth Kindler, Aaron Garzon, George Fink filed Critical Pharmos Corp
Priority to EP03794042A priority Critical patent/EP1545504A2/en
Priority to AU2003256059A priority patent/AU2003256059A1/en
Priority to CA002497164A priority patent/CA2497164A1/en
Priority to JP2004534012A priority patent/JP2006502159A/en
Publication of WO2004021974A2 publication Critical patent/WO2004021974A2/en
Publication of WO2004021974A3 publication Critical patent/WO2004021974A3/en
Priority to IL16680505A priority patent/IL166805A0/en
Priority to US11/073,250 priority patent/US20050192341A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising as an active ingredient non-psychotropic cannabinoids for preventing, alleviating or diminishing cognitive impairment resulting from certain types of surgery, diseases or viral infections, fetal distress, pre-term or low weight delivery, from medical intervention such as certain types of medication, irradiation or electroconvulsive therapy, or for prophylactic use in populations exhibiting mild cognitive impairment, and other populations at risk for chronic neurodegenerative diseases.
PCT/IL2003/000735 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment WO2004021974A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03794042A EP1545504A2 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment
AU2003256059A AU2003256059A1 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment
CA002497164A CA2497164A1 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment
JP2004534012A JP2006502159A (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids to prevent cognitive impairment
IL16680505A IL166805A0 (en) 2002-09-05 2005-02-10 Non-psychotropic cannabinoids for prevention of cognitive impairment
US11/073,250 US20050192341A1 (en) 2002-09-05 2005-03-04 Non-psychotropic cannabinoids for prevention of cognitive impairment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40895802P 2002-09-05 2002-09-05
US60/408,958 2002-09-05
PCT/IL2003/000604 WO2004023340A2 (en) 2002-09-05 2003-07-23 Non-psychotropic cannabinoids for prevention of cognitive impairment
ILPCT/IL03/00604 2003-07-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/073,250 Continuation US20050192341A1 (en) 2002-09-05 2005-03-04 Non-psychotropic cannabinoids for prevention of cognitive impairment

Publications (2)

Publication Number Publication Date
WO2004021974A2 WO2004021974A2 (en) 2004-03-18
WO2004021974A3 true WO2004021974A3 (en) 2004-05-06

Family

ID=31980345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000735 WO2004021974A2 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment

Country Status (3)

Country Link
JP (1) JP2006502159A (en)
AU (1) AU2003256059A1 (en)
WO (1) WO2004021974A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
WO1995020958A1 (en) * 1994-02-07 1995-08-10 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6211230B1 (en) * 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
WO1995020958A1 (en) * 1994-02-07 1995-08-10 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6211230B1 (en) * 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRAIN RESEARCH, vol. 674, no. 1, 1995, pages 55 - 62 *
DATABASE BIOSIS [online] SHOHAMI E. ET AL.: "Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat", XP002975245, accession no. STN Database accession no. 1995:209964 *

Also Published As

Publication number Publication date
JP2006502159A (en) 2006-01-19
WO2004021974A2 (en) 2004-03-18
AU2003256059A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
WO2006133941A3 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007119098A3 (en) Use of an nmda receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
WO2005094799A3 (en) Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
CA2582289C (en) Inhibition of tumour cell migration
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
PL375621A1 (en) Pharmaceutical compositions comprising flavonoids and menthol
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
ES2187300A1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
WO2001076555A3 (en) Lipid-based drug delivery systems for topical application
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
MX2021010213A (en) Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient.
EP4115895A4 (en) Tea composition having efficacy for preventing or improving respiratory diseases, and pharmaceutical composition comprising same
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
BRPI0516545A (en) use of lavender oil for prophylaxis and treatment of neurasthenia, somatization disorders and other stress-related illnesses
WO2004021974A3 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2004023340A8 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2006089120A3 (en) Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1232748A4 (en) Substituted nitrobenzene derivatives as medicines and other useful uses thereof
WO2003043966A3 (en) Clusianon isomers and use thereof
Range et al. Hearing Loss & Tinnitus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003794042

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 166805

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003256059

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2497164

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11073250

Country of ref document: US

Ref document number: 2004534012

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003794042

Country of ref document: EP